Proglucagon products in plasma of noninsulin-dependent diabetics and nondiabetic controls in the fasting state and after oral glucose and intravenous arginine.
Open Access
- 1 February 1991
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 87 (2), 415-423
- https://doi.org/10.1172/jci115012
Abstract
We investigated the major products of proglucagon (PG) processing in plasma in the fasting state, after intravenous arginine and after an oral glucose load in noninsulin-dependent diabetics (NIDDM) and in weight matched controls using specific radioimmunoassays and analytical gel filtration. In the fasting state the glucagonlike peptide-1 (GLP-1) immunoreactivity was significantly elevated in the NIDDM group compared with the control group. Both after intravenous arginine and after an oral glucose load a rise in the plasma concentrations of all immunoreactive moieties measured was seen. All integrated incremental responses after intravenous arginine were identical in the two groups. After oral glucose the insulin concentrations in plasma were lower and the concentrations of all proglucagon products were higher in the NIDDM group compared to the control group. The gel filtration analysis showed that arginine stimulated the secretion of pancreatic glucagon (PG 33-61), major proglucagon fragment (PG 72-158) and probably GLP-1 (PG 72-107 amide) in both groups, whereas oral glucose stimulated the secretion of glicentin (PG 1-69) and intestinal GLP-1 (PG 78-107 amide), an insulinotropic hormone. The elevated levels of immunoreactive GLP-1 in diabetics in the fasting state were mainly due to an increased concentration of major proglucagon fragment.This publication has 20 references indexed in Scilit:
- GLUCAGON-LIKE PEPTIDE-1 7-36: A PHYSIOLOGICAL INCRETIN IN MANThe Lancet, 1987
- Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas.Journal of Clinical Investigation, 1987
- Truncated glucagon‐like peptide I, an insulin‐releasing hormone from the distal gutFEBS Letters, 1987
- Molecular forms of glucagon‐like peptides in manFEBS Letters, 1985
- Diminished B cell secretory capacity in patients with noninsulin-dependent diabetes mellitus.Journal of Clinical Investigation, 1984
- Conversion of proglucagon in pancreatic alpha cells: the major endproducts are glucagon and a single peptide, the major proglucagon fragment, that contains two glucagon-like sequences.Proceedings of the National Academy of Sciences, 1984
- The primary structure of porcine glicentin (proglucagon)Regulatory Peptides, 1981
- Immunoreactive glucagon and insulin C-peptide in man after resection of the pancreas and total pancreatectomyThe American Journal of Surgery, 1980
- Radioimmunological determination of pancreatic and gut glucagon in plasmaDiabetologia, 1971
- Studies of pancreatic alpha cell function in normal and diabetic subjectsJournal of Clinical Investigation, 1970